SohSoh's Posts
Nairaland Forum › SohSoh's Profile › SohSoh's Posts
... |
I'm going to share two set of information with you and I believe without proper investigation you and chat GPT would have said the companies were legit 1:: EFishery an Indonesian Agricultural Company Link :: A TikTok Clip by Bloomberg ::: https://vt.tiktok.com/ZSBX9Pbkw/ Picture also attached 2: Tingo Food or Tingo Group by dozy mmobuosi Picture also attached read about it My opinion:: people in Nigeria fell for CBEX and if someone is being scammed and you tried to correct they they will you names benzmatic:
|
The same compnay that took loan from FCMB in 2022/2023 and couldnt reply back and converted the loan to euqity ... they can't issue Commercial Paper because they will have poor rating emmaodet: |
My partner my friend im sorry we are in the same boat together ... one cold beer for you ![]() Streetinvestor2: |
I didn't include MECURE in the list cos it only gave me about 10% captial appreciation also didn't include AIICO in the list too cos it gave me about 10-15% captial appreciation as of the time i posted or made the list. the stocks on the list are my winners... (30-100% capital appreciation) and to be honest I already brought MECURE before I even came here to promote it.. Panadee:
|
What r u talking about... i gave Mecure as a buy recommendation few weeks ago. Or you want to say Mecure is a scam company like Ellah Lakes Streetinvestor2: |
Ellah Lakes Ellah Lakes ![]() As seen on nairametrics 1: in year September 2022 : took over Adarice Farms from Enugu state government, no pictures of the Rice in the Market, but in 2024 & 2023 declared zero revenue 2: September 2022, claimed to make acquisitions, yet those companies acquired in 2023 & 2024 made zero revenue 3: September 2023 , Got SEC approval to raise 2.9billion yet in 2023 $ 2024 made zero revenue 4: October 2023 plans to invest 400million usd… yet in same 2023, and 2024 made zero revenue No be juju be that
|
Did you read this news article ... a company can couldn't repay or manage 940 million loan... is seeking 250billion They should issue commercial paper least see if they can repay since company like Dangote, Fidson, Mecure industries are all issuing commercial paper Ellah Lakes should issue commercial paper .... Princkez:
|
#EllahLakes I can't upload the TikTok Video from Bloomberg #EllahLakes Link Attached another Agricultural company that sent fake number is to investors TikTok Link By Bloomberg ::: https://vt.tiktok.com/ZSBX9Pbkw/ Now the same Ellah Lakes wants to raise 250 billion same compnay with Zero revenuefor 2 consecutive years .. na Loco,Megawealth and Street Investor go buy am ![]()
|
July 14 is on Monday ..... market should reward banks that have met this recapitalization or banks that submit a good steady plan ... lol 😆
|
Using Tingo Foods as my example 1: Google to and search " Tingo Foods" looks at the videos section the dozy guy did interview and stake holders meeting 2: why aren't there pictures of Ellah Lake produces on the internet, if the company produces any thing surely the pictures would have made it to the internet, no pictures of equipment or asset used by the company.. Even Lagos State wey they produce RICE the picture of the rice plenty for internet crownprince2017:
|
Ellah Lakes might be a scam or phony company All the pictures of ellah lakes on the internet are digital, and not real, there are no pictures or videos of or from the business operations or behind the scenes, assets or equipments, used by the company. Using dangote Refinery as an example we have seen pictures and videos of and from the refinery. Cutix I've seen there product in the market. Also in 2020 Ellah Lakes had zero revenue ... the company might be a scam... and before alot of you are quick to argue... there is the case of " Dozy Mmobuosi " (read about it) of " Tingo Foods" that faked a company like Ellah Lake and listed it on NYSE Ellah Lake might be a phony company or scam company ....
|
I want to get this off my mind…to some extent a lot of you on this forum are hypocrites. Few weeks ago I wrote a buy recommendation for MECURE as a better BUY than FIDSON AND NEIMETH as of that time and shared it here the same way Loco does and a vast majority of the people here shut it down and said Fidson was a better option and went and pushed the price of FIDSON up Price above MECURE, if that was to taunt me, I don’t care Few days back i saw a lot of you are now recommending NEIMETH the books ain’t good. So I came to the conclusion that a lot of you here are institutional traders and not retail traders like ME… Cos a lot of the information LOCO shares are not easily available on the internet And was already posting about EllahLakes long before the CEO did that interview… just be careful cos it looks a lot like insider trading and the ship post about C&I Leasing that also is not available to retail investors or traders like me self. Why I’m writing all these ? is because if you guys here were, welcoming maybe I would have tried more to share some of my trade ideas because when I buy a stock I don’t come here to try and promote it for it too moveNow this is my trade over the last 3 months… (PICTURE ATTACHED) While LOCO is only promoting Champion, C&I Leasing, EllahLakes : by my calculations: LOCO has made 495% profit increase in his trade with these 3 stocks with a lot of promotion And ME : 531% ( picture attached my BUY prices) I didn't include Champion cos I brought Champion long before he started promoting it here And there are stocks I brought that gave me 15-20% ( like AIICO, Aradel and Legend internet) So my 530% should be close to 600-700% No Promotion just Good Trading!! Drops Mic !!
|
Your analysis is sharp and well-structured, it demonstrates a clear understanding of valuation metrics, earnings quality, and risk-reward tradeoffs. That said, I remain confident in my BUY recommendation on MeCure. While I respect your view that Fidson may offer stronger fundamentals at this time. it’s a free market, and that’s the beauty of it. Differing views, based on distinct strategies and time horizons, are what make markets function. now :: I'm a trader, just looking for my next take profit, if the stock goes up fine I'll take my profit and walk away, if it goes down, I'll take my loss and walk away, but so far my analysis, that I have used previously has allowed me to take trades like this. """ explanation to the photos attached """ 1: my entry price for custodian was @18.10 on 15 may 2025, and on17 May. Nairametrics released that article as to why custodian might be undervalued, fast forward to 6 days ago, the CEO of Toyota brought 150Mn shares at 3Bn. and recently, custodian was among the stock recommendation from Morgan capital. All these i consider catalyst to cause the price to move up ward. 2: my buy and sell entry for UPL 3: My entry for champion, which crossed well over 100% return, I'm not an investor, looking to buy and hold for the next 2/3 years like someone said about CUTIX. I'm just looking for my next take profit. bovali:
|
WHO IS PAYING BIG DIVIDENDS LATELY, EVEN Champion breweries THAT MADE 21 BILLION IN EARNINGS AND 900MILLION + PROFIT ONLY PAID ABOUT 6KOBO megawealth01: |
AGAIN YOU GUYS ARE FAILING TO SEE THE POINT, MECURE INDUSTRIES PLC " CURRENTLY " IS A BETTER BUY THAN FIDSON, WHICH IS WHY I'M RECOMENDING IT AS A CURRENT BUY RECOMMENDATION. Sunrisepebble: |
my " BUY " recommendation on MeCure Industries Plc is based on a combination of strong fundamentals and prudent financial management. Despite the repayment of a significant portion of their commercial paper obligations, the company has remained profitable, posting a ₦568.71 million net profit in Q1 2025 and delivering 65% year-on-year revenue growth. This reflects a resilient business model, disciplined capital allocation, and a management team that has demonstrated both operational efficiency and strategic foresight. The company's ability to grow earnings while meeting debt obligations is a key indicator of underlying strength—not just good management, but effective execution. megawealth01: |
Locotrader:
|
Here Date : June 1 2025 MECURE INDUSTRIES : Q1 Result : As At 31 March 2025. Link :: https://africanfinancials.com/document/ng-mecure-2025-ir-q1/ Google Search Word : mecure industries 2025 megawealth01:
|
Date : June 1 2025 MECURE INDUSTRIES : Q1 Result : As At 31 March 2025. Link :: https://africanfinancials.com/document/ng-mecure-2025-ir-q1/ Google Search Word : mecure industries 2025
|
DATE : 1 JUNE 2025 Mecure Industries Plc — BUY Recommendation Summary Executive Overview: Mecure Industries Plc delivered an impressive financial performance in FY 2024/2025, signaling strong operational execution and growth momentum: Revenue surged by 45% year-on-year to ₦46.03 billion. Profit After Tax (PAT) stood at a solid ₦2.33 billion. The company is well-positioned for sustainable expansion within Nigeria’s fast-evolving healthcare sector. Capital & Strategic Moves: Successfully expanded its Commercial Paper (CP) program from ₦20 billion to ₦40 billion, enabling enhanced flexibility in funding growth initiatives. Raised over ₦26 billion through CP issuances within 16 months at attractive market rates, reflecting high investor demand. Demonstrates strong access to capital markets, showcasing disciplined and effective financial management. Valuation & Financial Metrics: Price-to-Earnings (P/E) Ratio: ~19.0x, in line with peers in the healthcare and pharmaceutical industry. Dividend Yield: ~1.35%, with a ₦0.15 dividend per ₦11.10 share, delivering consistent shareholder returns. Maintains an efficient capital structure, supported by active treasury operations and funding agility. Key Investment Drivers: Strong Earnings Momentum: Sustained revenue growth and rising profitability highlight operational strength. Strategic Capital Deployment: Ongoing CP issuances demonstrate proactive and efficient funding strategies. Reliable Dividend Payments: Consistent dividend distribution underscores commitment to shareholder value creation. Healthcare Sector Expansion: Mecure is well-positioned to benefit from increasing local demand, import substitution, and rising health expenditures in Nigeria. Institutional Investor Confidence: Robust participation in the company’s CP program reflects strong market trust and long-term confidence in its strategy. Conclusion: Mecure Industries Plc stands out as a high-quality investment opportunity within Nigeria’s pharmaceutical sector. With solid financials, attractive valuation, dividend income potential, and a clear growth trajectory, it presents a compelling case for investors seeking both value and expansion upside. We assign a BUY recommendation based on Mecure’s proven performance, strategic capital initiatives, and long-term market potential.
|
IF YOU LOOK HERE, AT REVENUE VS PEERS : I PLACED IT ABOVE NEIMETH AND BELOW FIDSON Heishere:
|
IF YOU LOOK HERE, AT REVENUE VS PEERS : I PLACED IT ABOVE NEIMETH AND BELOW FIDSON SohSoh: |
Thank you for your comment. To clarify, this is a current BUY recommendation for Mecure Industries Plc, GeeKudi: |
Thank you for your comment. To clarify, this is a current BUY recommendation for Mecure Industries Plc, Heishere: |
" BUY " RECOMENDATION : MECURE INDUSTRIES Executive Summary Mecure Industries Plc has demonstrated resilient financial performance for the fiscal year 2024/2025, underpinned by strong revenue growth, rising operating profitability, consistent commercial paper issuances, and a dividend payout to shareholders. With a year-on-year (YoY) revenue increase of 45% to ₦46.03 billion and a Profit After Tax (PAT) of ₦2.33 billion, the company remains well-positioned for sustainable expansion within Nigeria’s evolving healthcare landscape. Given its favorable growth indicators, attractive valuation relative to peers, and continued investor confidence via capital market instruments, we recommend a BUY rating for Mecure Industries Plc. Strategic Developments & Capital Structure Mecure Industries has shown disciplined financial stewardship through the issuance of Commercial Paper (CP) to fund working capital and expansion needs. The company expanded its CP programme from ₦20 billion to ₦40 billion, demonstrating its creditworthiness and market confidence. Notable CP issuances include: • Series 4 (April 2025): ₦9 billion at 22.5468% discount (267-day tenor) • Series 3 (June 2024): ₦6.5 billion at 23.26% • Series 2 (Feb 2024): ₦6.03 billion at 18.20% • Series 1 (Dec 2023): ₦5.12 billion at 16.68% The cumulative issuance of over ₦26 billion within a 16-month period reinforces the company’s access to debt capital markets and a robust funding strategy. While Fidson leads in revenue and PAT, Mecure exhibits a balanced profile of profitability, dividend distribution, and manageable finance costs. Neimeth, despite high revenue growth, remains unprofitable and exposed to FX volatility. ⸻ Valuation & Investment Case • Price-Earnings Ratio (P/E) (Est.): ~19.0x – In line with industry averages • Dividend Yield: ~1.35% (₦0.15 per ₦11.10 share price) • Debt Profile: Actively managed through CP issuances with market-reflective discount rates ⸻ Key Investment Drivers 1. Strong Earnings Momentum: PAT of ₦2.33bn and revenue growth of 45% YoY demonstrates robust operational efficiency. 2. Strategic Use of Debt Capital: CP programme shows active treasury management and funding agility. 3. Dividend Payment: Indicates shareholder value creation and financial stability. 4. Sector Growth: Nigeria’s healthcare and pharmaceutical sector continues to benefit from increased health spending, import substitution policies, and rising demand for local manufacturing. 5. Institutional Confidence: CP programme expansion and successful issuance point to strong investor trust and liquidity support. ⸻ Risks to Outlook • Rising finance costs (₦4.98 billion) could impact bottom-line margins if not carefully managed. • Heavy reliance on debt markets for working capital raises leverage concerns, particularly in high-interest environments. • Macroeconomic risks including FX fluctuations and inflation could affect input costs and consumer demand. ⸻ Conclusion Mecure Industries Plc presents a solid investment opportunity with strong fundamentals, strategic debt management, dividend income potential, and medium-term growth outlook. For investors seeking exposure to Nigeria’s pharmaceutical sector, Mecure offers a compelling mix of value, yield, and expansion capacity. We assign a BUY recommendation, supported by stable financials, expanding operations, and disciplined capital management. ⸻ This recommendation is for informational purposes only and does not constitute investment advice. Investors are encouraged to conduct independent analysis or consult a licensed financial advisor before making any investment decision.
|
OMATEK ON FULL BID
|
Executive Summary Mecure Industries Plc has demonstrated resilient financial performance for the fiscal year 2024/2025, underpinned by strong revenue growth, rising operating profitability, consistent commercial paper issuances, and a dividend payout to shareholders. With a year-on-year (YoY) revenue increase of 45% to ₦46.03 billion and a Profit After Tax (PAT) of ₦2.33 billion, the company remains well-positioned for sustainable expansion within Nigeria’s evolving healthcare landscape. Given its favorable growth indicators, attractive valuation relative to peers, and continued investor confidence via capital market instruments, we recommend a BUY rating for Mecure Industries Plc. Strategic Developments & Capital Structure Mecure Industries has shown disciplined financial stewardship through the issuance of Commercial Paper (CP) to fund working capital and expansion needs. The company expanded its CP programme from ₦20 billion to ₦40 billion, demonstrating its creditworthiness and market confidence. Notable CP issuances include: • Series 4 (April 2025): ₦9 billion at 22.5468% discount (267-day tenor) • Series 3 (June 2024): ₦6.5 billion at 23.26% • Series 2 (Feb 2024): ₦6.03 billion at 18.20% • Series 1 (Dec 2023): ₦5.12 billion at 16.68% The cumulative issuance of over ₦26 billion within a 16-month period reinforces the company’s access to debt capital markets and a robust funding strategy. While Fidson leads in revenue and PAT, Mecure exhibits a balanced profile of profitability, dividend distribution, and manageable finance costs. Neimeth, despite high revenue growth, remains unprofitable and exposed to FX volatility. ⸻ Valuation & Investment Case • Price-Earnings Ratio (P/E) (Est.): ~19.0x – In line with industry averages • Dividend Yield: ~1.35% (₦0.15 per ₦11.10 share price) • Debt Profile: Actively managed through CP issuances with market-reflective discount rates ⸻ Key Investment Drivers 1. Strong Earnings Momentum: PAT of ₦2.33bn and revenue growth of 45% YoY demonstrates robust operational efficiency. 2. Strategic Use of Debt Capital: CP programme shows active treasury management and funding agility. 3. Dividend Payment: Indicates shareholder value creation and financial stability. 4. Sector Growth: Nigeria’s healthcare and pharmaceutical sector continues to benefit from increased health spending, import substitution policies, and rising demand for local manufacturing. 5. Institutional Confidence: CP programme expansion and successful issuance point to strong investor trust and liquidity support. ⸻ Risks to Outlook • Rising finance costs (₦4.98 billion) could impact bottom-line margins if not carefully managed. • Heavy reliance on debt markets for working capital raises leverage concerns, particularly in high-interest environments. • Macroeconomic risks including FX fluctuations and inflation could affect input costs and consumer demand. ⸻ Conclusion Mecure Industries Plc presents a solid investment opportunity with strong fundamentals, strategic debt management, dividend income potential, and medium-term growth outlook. For investors seeking exposure to Nigeria’s pharmaceutical sector, Mecure offers a compelling mix of value, yield, and expansion capacity. We assign a BUY recommendation, supported by stable financials, expanding operations, and disciplined capital management. ⸻ This recommendation is for informational purposes only and does not constitute investment advice. Investors are encouraged to conduct independent analysis or consult a licensed financial advisor before making any investment decision.
|
? is because if you guys here were, welcoming maybe I would have tried more to share some of my trade ideas because when I buy a stock I don’t come here to try and promote it for it too move